LitCovid-sentences  

PMC:7696151 / 66337-71299 JSONTXT 3 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T425 0-6 Sentence denotes 2.4.1.
T426 7-26 Sentence denotes Autoimmune Diseases
T427 27-244 Sentence denotes HCQ belongs to the group of the disease-modifying antirheumatic drug (DMARD), which comprises drugs that are not chemically relted, sharing the same efficacy in dampening the progression of rheumatoid arthritis [122].
T428 245-390 Sentence denotes It often occurs also that glucocorticoids or natural antioxidant substances are included in the coadjutant therapy of rheumatoid arthritis [123].
T429 391-653 Sentence denotes A multicenter, randomized clinical trial analyzed the tolerability and the efficacy of combined therapy, including HCQ, sulphasalazine, MXT, and PRD with respect to the use of a single antirheumatic drug in the caring of early rheumatoid arthritis for two years.
T430 654-759 Sentence denotes A total of 195 patients were equally divided into two groups to follow the assigned therapeutic protocol.
T431 760-988 Sentence denotes The primary aim of clinical remission was achieved after one year by 24 of the 97 patients under combinatory therapy, while only by 11 of 98 single-drug therapy users, but this trend was further confirmed during the second year.
T432 989-1149 Sentence denotes After one year, 75% of subjects under combinatory therapy and 60% of those under single-therapy reached clinical improvement, intended as 50% clinical response.
T433 1150-1264 Sentence denotes In terms of tolerability, the cotreatment resulted not to be more dangerous with respect to the single drug [123].
T434 1265-1468 Sentence denotes In a prospective trial, patients with the diagnosis of rheumatoid arthritis were scheduled to receive cotreatment of sulphasalazine (1–3 g/day), MXT (7.5–15 mg/week), and HCQ (200 mg/day) for six months.
T435 1469-1594 Sentence denotes Significant improvements in clinical parameters revealed the efficacy of the cotreatment in counteracting endothelial injury.
T436 1595-1764 Sentence denotes Indeed, the blood concentrations of endothelial injury markers, mainly soluble E selectin and thrombomodulin, experienced a significant drop after the cotreatment [124].
T437 1765-2156 Sentence denotes Likewise, a single-blinded clinical trial on 281 patients confirmed the better therapeutic efficiency of cotreatment (25 mg/week MXT, 2 g/day of sulphasalazine, and 400 mg/day HCQ p.o. plus intramuscular injection (i.m.) doses of 120 mg of methylprednisolone or 80 mg of triamcinolone) with respect to single therapy after three months, without significant differences in side effects [125].
T438 2157-2516 Sentence denotes Proofs of the better antirheumatic potential of the combination of drugs with respect to single therapy derived from an observational study that evaluated the higher improvement of quality of patients’ life after one year of coadministration of MXT, HCQ, and corticosteroids with respect to single MXT, or HCQ, or their combination with corticosteroids [126].
T439 2517-2735 Sentence denotes Great insights in disease remission were provided by a clinical trial involving 17 patients with active rheumatoid arthritis where the chronic inflammatory status of joints was evaluated through the 18F-FDG PET method.
T440 2736-3007 Sentence denotes It was found that cotreatment with 7.5–15 mg/week of MXT, 2 g/day of sulphasalazine, 5 mg/kg/day of HCQ and a low dose of oral PRD (under 10 mg/day) is associated with a reduction of 30% in 18F-FDG uptake measures on PET imaging in 81% of patients after four weeks [127].
T441 3008-3114 Sentence denotes Although HCQ is effective and well-tolerated, other therapeutic alternatives have emerged in recent years.
T442 3115-3172 Sentence denotes Among them, monoclonal antibodies are the most promising.
T443 3173-3487 Sentence denotes In a multicenter open-label clinical trial, performed on 60 patients with juvenile idiopathic arthritis for 54 weeks, the combination of infliximab monoclonal antibodies with a conventional antirheumatic drug provided the better response in terms of disease inactivation with respect to DMARD administration [128].
T444 3488-3602 Sentence denotes In addition to rheumatoid arthritis patients, HCQ is also used in lupus erythematosus, another autoimmune disease.
T445 3603-3653 Sentence denotes Regarding lupus erythematosus, HCQ is widely used.
T446 3654-3993 Sentence denotes In vivo studies on a NZB/W F1 murine model of lupus showed that HCQ in combination with PRD (2.5 mg/kg/day and 1 mg/kg/day p.o.) decreased autoantibody production, as well as being able to inhibit toll-like receptor activation, resulting in the down-regulation of type I interferon (IFN-α) which is deeply implicated in lupus pathogenesis.
T447 3994-4302 Sentence denotes The efficacy of treatment is due to the ability of drugs to alter the expression of urinary and immune cell micro RNA that contribute to lupus progression by post-transcriptional modulation of genes involved in the immune response, pro-inflammatory cytokines production and toll-like receptor pathways [129].
T448 4303-4409 Sentence denotes In association with low-dose aspirin, HCQ is also indicated for thromboprophylaxis in patients with lupus.
T449 4410-4704 Sentence denotes The occurrence of thrombotic events was recorded for 13 years in 189 patients, showing that the cardiovascular complications were more frequent in patients treated only with aspirin, while HCQ (up to 600 mg) was associated with a stronger thrombo-protective effect in patients with lupus [130].
T450 4705-4854 Sentence denotes Thanks to its immunomodulatory properties, HCQ (20 mg/kg) was revealed to be useful in graft-versus-host disease, in combination with cyclosporine A.
T451 4855-4962 Sentence denotes They synergistically suppressed T cell response, allowing the reduction of the dose of drugs in mice [131].